PepGen Inc. Common Stock PEPG
i
Market datapartial · fetched 2026-11-13T02:29:58.366Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-13T00:37:58.673598135Z
FundamentalsAlpha Vantage · unavailable
PepGen Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | ||||||
| 45Δ | 5.07 | 132.1% | 8.2% | |||
| 50Δ | 5.21 | 130.4% | 7.2% | |||
| 55Δ | 5.08 | 103.7% | 6.4% | 5.34 | 128.7% | 6.3% |
| 60Δ | 5.47 | 127.0% | 5.4% | |||
| 65Δ | 5.61 | 125.3% | 4.5% | |||
| 70Δ | 5.74 | 123.6% | 3.5% | |||
| 75Δ | 5.87 | 121.9% | 2.6% | |||
| 80Δ | 6.06 | 124.5% | 1.8% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.07
- IV
- 132.1%
- B/E move
- 8.2%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.21
- IV
- 130.4%
- B/E move
- 7.2%
55Δ
- Pseudo strike
- 5.08
- IV
- 103.7%
- B/E move
- 6.4%
- Pseudo strike
- 5.34
- IV
- 128.7%
- B/E move
- 6.3%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.47
- IV
- 127.0%
- B/E move
- 5.4%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.61
- IV
- 125.3%
- B/E move
- 4.5%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.74
- IV
- 123.6%
- B/E move
- 3.5%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.87
- IV
- 121.9%
- B/E move
- 2.6%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.06
- IV
- 124.5%
- B/E move
- 1.8%
Options history
No recorded observations
Biotechnology
PGEN
Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
More →PHAT
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company is…
More →PHVS
Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies. The company is headquartered in Leiden, the…
More →PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary…
More →PRAX
Description unavailable
More →PRLD
Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized to target key…
More →